UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) K-1-accRegister to Unlock Ratings |
Performance History | 30/06/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 16.1 | 17.7 | -12.2 | 3.5 | 10.6 | |
+/-Cat | 11.7 | 2.4 | -3.9 | -8.0 | 4.8 | |
+/-B’mrk | 13.5 | 0.1 | -7.7 | -9.6 | 3.6 | |
Category: Europe Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar DM Eur TME NR EUR |
Key Stats | ||
NAV 26/07/2024 | EUR 6973275.24 | |
Day Change | 0.78% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
ISIN | LU0999556193 | |
Fund Size (Mil) 26/07/2024 | EUR 493.47 | |
Share Class Size (Mil) 26/07/2024 | EUR 13.95 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 17/07/2024 | 1.30% |
Investment Objective: UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) K-1-acc |
This actively managed sub-fund predominantly invests in equities, equity rights or other equity interests in companies domiciled or chiefly active in Europe. The UBS ESG consensus score is used to identify issuers/companies for the investment universe with strong environmental and social performance characteristics, or a strong sustainability profile. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Maximilian Anderl 23/07/2012 | ||
Jeremy Leung 01/04/2011 | ||
Inception Date 12/12/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) K-1-acc | 30/06/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 5.44 |
UBS (Irl) Inv Sel Eq Opp L/S € U-B | 4.86 | |
ASML Holding NV | Technology | 4.26 |
UBS (Irl) Inv Sel Eq Opp L/S I-B | 3.43 | |
Tryg A/S | Financial Services | 3.11 |
Increase Decrease New since last portfolio | ||
UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) K-1-acc |